CCM
NPCE icon

CAAS Capital Management’s Neuropace NPCE Stock Holding History

CAAS Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,000
Closed -$952K – 1068
2021
Q2 		$952K Buy
+40,000
New +$928K 0.02% 590

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAAS Capital Management's NPCE Position: Q3 2021 in Review

CAAS Capital Management sold out of Neuropace (NPCE) in Q3 2021, closing a stake of 40,000 shares — an estimated $952K sold.

CAAS Capital Management first reported a position in NPCE in Q2 2021 and held it in 1 quarter. The position peaked at $952K in Q2 2021. 39 funds tracked by Wall St. Rank hold NPCE as of Q3 2021.

  • CAAS Capital Management reported no remaining Neuropace position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 40,000 Neuropace shares in Q3 2021, an estimated $952K.
  • CAAS Capital Management first reported a position in Neuropace in Q2 2021 and held it in 1 quarter.
  • CAAS Capital Management's Neuropace position peaked at $952K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Neuropace as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.